Selzentry Labeling Includes New Warnings for People With Kidney Problems
By Myles Helfand
June 2, 2010
The CCR5 inhibitor Selzentry (Celsentri, maraviroc) should be used with caution by HIV-positive people with kidney problems, according to a U.S. Food and Drug Administration release. The release provides details on several changes that have just been made to the official drug labeling for Selzentry, all of which have to do with the renal (kidney) issues.
This is all pretty new information. Although it was previously known that some Selzentry dose adjustments were likely needed for people with kidney failure, that's also true of an awful lot of drugs, since the kidneys basically act as the body's filtration system -- and if they stop working, it seriously hurts the body's ability to prevent drug levels from building up dangerously.
The new Selzentry labeling will include a number of specific warnings and other information related to the kidneys, including:
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The Viral Truth
Subscribe to This Blog:
November 18, 2013 - HIV, Intersectionality and the Generation Gap: A Blog Entry by Becky Allen
October 30, 2013 - Is HIV/AIDS the Real American Horror Story?
October 21, 2013 - Food for Thought: An Observation on Longevity -- A Blog Entry by Chris Lavery
October 8, 2013 - Endure, Remember, Forgive: A Blog Entry by Becky Allen
October 2, 2013 - TheBody.com Goes to the Big Easy: Reflections on USCA 2013
A Brief Disclaimer:
The opinions expressed by TheBody.com's bloggers are entirely their own, and do not necessarily reflect the views of TheBody.com itself.